المصدر: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05904730Test

Other URLs: https://pubmed.ncbi.nlm.nih.gov/24755544Test/
https://www.pennmedicine.org/news/news-releases/2022/november/why-cancers-caused-by-brca-mutations-recurTest
https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-021-00193-yTest

المصدر: A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05363605Test

Other URLs: http://fusionpharma.comTest

المؤلفون: Byondis B.V.

المصدر: ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04602117Test

المصدر: A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04464967Test